
AVROBIO AVRO
Quarterly report 2026-Q1
added 05-07-2026
AVROBIO Accounts Payables 2011-2026 | AVRO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables AVROBIO
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 M | 976 K | 409 K | 384 K | 3.49 M | 2.68 M | 3.95 M | 2.78 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.95 M | 384 K | 1.97 M |
Quarterly Accounts Payables AVROBIO
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.55 M | 1.48 M | 2.8 M | 6.25 M | 976 K | 2.64 M | 4.09 M | 243 K | 409 K | 910 K | 1.07 M | 591 K | 384 K | 1.81 M | 28 K | 4.04 M | 3.49 M | 2.97 M | 2.03 M | 2.7 M | 2.68 M | 2.68 M | 2.68 M | 2.68 M | 3.95 M | 3.95 M | 3.95 M | 3.95 M | 2.78 M | 2.78 M | 2.78 M | 2.78 M | 527 K | 527 K | 527 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.25 M | 28 K | 2.31 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
1.73 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 16.87 | -2.49 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.24 M | $ 7.47 | -4.6 % | $ 205 M | ||
|
Athira Pharma
ATHA
|
4.59 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
265 K | - | -32.59 % | $ 7.61 M | ||
|
Coherus BioSciences
CHRS
|
9.92 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.63 | 2.52 % | $ 434 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
3.38 M | - | - | $ 231 M | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.16 M | $ 3.36 | -3.72 % | $ 5.53 M | ||
|
Eton Pharmaceuticals
ETON
|
11 M | $ 30.26 | 1.0 % | $ 814 M | ||
|
Exelixis
EXEL
|
29.6 M | $ 50.13 | -1.9 % | $ 13.6 B | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
463 K | $ 0.72 | -1.58 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
65.1 M | $ 3.12 | - | $ 649 M | ||
|
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Fortress Biotech
FBIO
|
14.2 M | $ 2.41 | 4.78 % | $ 67.2 M | ||
|
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | ||
|
Forte Biosciences
FBRX
|
9.99 M | $ 23.11 | -3.55 % | $ 299 M | ||
|
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 21.32 | -1.16 % | $ 2.71 B | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
4.64 M | $ 9.75 | 5.52 % | $ 279 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
3.98 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M |